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Why clinical guidelines are desirable and important
Properly understood and employed, evidence-based medi-
cine (EBM) is a tool of considerable value for medicine and
neuro-oncology [1]. It provides a secure, scientiﬁcally-
defensible base for clinical practice and practice improve-
ment. However, pursued on an individual case-by-case
basis, in purest form, it can be inefﬁcient and time con-
suming, particularly for health providers with extremely
busy clinical practices. Clinical guidelines based on the best
evidence available, developed and regularly updated by
subject matter experts, focusing on common and important
clinical scenarios and questions, have the potential to be
very desirable, useful, and efﬁcient EBM tools for opti-
mizing patient care.
Clinical practice parameter guidelines are deﬁned as
‘systematically developed statements to assist practitioner
and patient decisions about appropriate health care for
speciﬁc individual circumstances’ [2]. An advantage of
utilizing guidelines in clinical decision-making over sole
reliance on randomized controlled trial (RCT) results, is
that they take professional experience into account in an
aggregate and more systematic manner, rather than on an
individual or ad hoc basis [3]. Not only are more ‘‘experts’’
involved in the consensus process (diluting out outliers in
opinion), but, in an evidence-based guidelines development
process, the opinions solicited are the experts’ opinions
about the collected evidence in the literature, rather than
simply their own personal opinions regarding the subject.
Multidisciplinary, evidence-linked clinical practice
parameter guidelines, based on the most rigorous evidence-
based methodology, offer the potential of reducing unex-
plainable variation in clinical practice while elevating the
quality of patient care to the highest levels supported by the
best available, and most up-to-date, evidence. They also
have the potential to clearly point out where critical evi-
dence ‘‘gaps’’ exist in areas important to clinical care that
can then subsequently be ﬁlled by directed research plan-
ning and investment [4]. The goal of this guideline initia-
tive is to optimize the care and outcome of our patients
with brain metastases, by providing the most methodo-
logically valid, evidence-linked treatment recommenda-
tions in a user-friendly and comprehensive manner, for
real-world clinical scenarios encountered by clinicians and
patients every day.
The healthcare policy implications of clinical practice
parameter guidelines are very real and deserve the careful
attention of both individual practitioners and our national
medical professional organizations. Legislation efforts
currently active in Washington include language focusing
on development and inclusion of ‘‘appropriateness criteria’’
as a means of restricting medical care and reducing med-
ical costs. They also include language focusing on the
development and funding of comparative effectiveness
research analyzing clinical effectiveness, and not just cost
effectiveness. Each of these efforts will likely lead to a
search for the best available clinical practice guidelines in
key public health impact areas for the purpose of improv-
ing value for every healthcare dollar spent, as well as
reducing cost through practice restriction. It is in our
patients’ interest, as well as our own as patient advocates,
to ensure the availability of the highest quality guidelines
S. N. Kalkanis (&)
Department of Neurosurgery, Henry Ford Health System,
2799 West Grand Blvd, K-11, Detroit, MI 48202, USA
e-mail: kalkanis@neuro.hfh.edu; skalkan1@hfhs.org
M. E. Linskey
Department of Neurosurgery, University of California-Irvine
Medical Center, Orange, CA, USA
123
J Neurooncol (2010) 96:7–10
DOI 10.1007/s11060-009-0065-4based on a rigorous methodology, where strength of rec-
ommendations cannot exceed the strength of available
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Why brain metastases are an important area
for clinical guideline development
Secondary brain tumors, or brain metastases, are 4–5 times
more common in incidence than primary brain tumors [5].
Furthermore, by deﬁnition, metastatic brain tumors imply
primary cancers that can span the full gamut of organ-
based subspecialty clinical practice in medicine. Thus,
from a public health impact, evidence-linked clinical
practice parameter guidelines regarding the care of patients
with metastatic brain tumors are likely to positively impact
more patients, as well as more medical practitioners, than
any other potential topic within neuro-oncology.
How can clinicians and patients best navigate through
the myriad of treatment decision pathways for brain
metastases?
According to the 2008 American Cancer Society Registry,
approximately 1.4 million Americans are diagnosed with
cancer every year [6] and up to 40% of these patients—over
a half million people annually—will go onto develop one or
more brain metastases [5]. While lung and breast are the
most common tumor types, many malignancies metastasize
to the brain. Treatment decisions must be individualized
basedonacomplexarrayofbothpatient-speciﬁcandtumor-
speciﬁc characteristics, especially since the number of
therapeutic options has grown considerably over the past
two decades.
A paradigm shift has occurred in the evolution of how
we treat patients with brain metastases. No longer relegated
to the realm of palliation with an expectation of a rapid
neurological decline and inevitable neurological demise,
patients with brain metastases now have a myriad of
aggressive treatment options available to them, resulting in
a longer life expectancy and better quality of life. With the
use of markedly improved local control measures, patients
are now often just as likely to succumb from their systemic
disease, than from their brain tumor(s).
Whole brain radiation therapy (WBRT) has been the
mainstay of metastatic brain tumor therapy for decades
through the mid-1990s [7]. However, more recent data has
highlighted the potential beneﬁt of more aggressive local
control measures involving surgical resection and stereo-
tactic radiosurgery (SRS) in addition to WBRT [8, 9]. Even
more recently, SRS alone, surgical resection and SRS,
chemotherapy, and several cutting-edge investigational
adjuvant therapies have come under consideration. The
typical brain metastasis patient now encounters not only a
general medical oncologist and a radiation oncologist, but
also a neurosurgeon, and a neuro-oncologist.
Guidelines for creating guidelines
The ultimate validity of any guideline is critically related to
three key factors: (1) the composition of the guideline
panel and its process, (2) the identiﬁcation and synthesis of
the evidence, and (3) the method of guideline construction
applied [10, 11]. The panel composition is crucial, both for
ultimate acceptance of the guidelines by practicing physi-
cians and for its critical inﬂuence on the recommendation
step of guideline construction. Successful introduction of a
guideline requires that all key disciplines contribute to its
development to ensure ownership and support [12]. While
sponsored by the American Association of Neurological
Surgeons (AANS), the Congress of Neurological Surgeons
(CNS), and the AANS/CNS Joint Tumor Section, this
guideline initiative was pro-actively designed to be as
inclusive of other related disciplines as possible to maxi-
mize its quality, acceptance, and potential impact. In
addition to prominent neurosurgeons involved in surgical
neuro-oncology and stereotactic radiosurgery, the multi-
disciplinary writing panel includes nationally recognized
experts from radiation oncology, medical oncology, and
neuro-oncology.
In order to maximize the quality of the identiﬁcation and
synthesis of evidence as well as the speed and efﬁciency of
guideline development, the three organizations sponsoring
this initiative contracted with McMaster University to
facilitate the process over an anticipated twelve month
timetable. The McMaster Evidence-Based Practice Center
(EPC) is one of 15 EPCs federally funded through grants
from the Agency for Healthcare Research and Quality
(AHRQ) to assist in promoting quality of healthcare,
reducing its cost, improving patient safety, decreasing
medical errors, and broadening access to essential services
by supporting outcomes studies, and implementing their
ﬁndings through the dissemination of clinical guidelines in
the U.S. Extremely expert in EBM techniques, and with an
experienced staff and asset infrastructure in place, they
have been instrumental in helping the author group expe-
dite their work at the highest possible quality level, without
any diminution of thoroughness or scientiﬁc rigor.
The choice of a rigorous evidence-linked recommen-
dation methodology over an informal or formal consensus
methodology was purposefully chosen to maximize rigor of
the result and prevent over-stepping the strength of avail-
able evidence. Consensus guidelines can produce very
valid and useful conclusions, however, one of their main
weaknesses is that they often lead to recommendations
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dence to recommend one approach over another. Truly
evidence-linked guidelines are important for pointing out
recommendations based on pertinent evidence, but they
have an even more important function in allowing and
preserving provider autonomy and ﬂexibility in areas
where insufﬁcient evidence or strength of evidence exists
to recommend standardization. The fear of ‘‘cook book’’
medicine resulting from the application of guidelines to
clinical practice is best mitigated by adherence to strict
evidence-linked methodology [4].
How this process is different
Not all guidelines are equivalent in quality. According to
Woolf, there are three main methods of guideline devel-
opment—informal consensus, formal consensus, and evi-
dence-linked development [13]. From the standpoint of
evidence based medicine (EBM), only the latter has evi-
dentiary status for EBM decision-making. Indeed, the U.S.
Institute of Medicine hopes to eventually restrict the use of
the term ‘‘guideline’’ to systematically developed advisory
statements created according to validated methodology [2].
Some consider consensus guidelines as intellectually sus-
pect by reﬂecting expert opinion, which when promulgated
as a ‘‘guideline,’’ can formalize unsound practice [14].
Without strict adherence to systematic and validated
methodology, panelists may be pooling ignorance as much
as distilling wisdom [15]. Some guidelines are of ques-
tionable quality and there have been calls for guidelines on
how to devise guidelines [16].
The U.S. National Guidelines Clearinghouse (NGC) [
http://www.guideline.gov] currently includes guidelines
that have been formed through expert consensus alongside
those based in systematic evidence-based methodology. It
also includes guidelines that have been created by special
interest and advocacy groups, subspecialty organizations,
insurance companies, private consulting ﬁrms, cross-rep-
resentative panels designed to include representatives from
all potential stakeholders, and Evidence-Based Practice
Centers (EPCs). Many of these guidelines conﬂict with one
another, and there is currently no means of resolving or
adjudicating these conﬂicts other than individual providers
or oversight organizations making their own decision(s) as
to which should take a position of supremacy or authority.
By clearly outlining our search process as facilitated by
the McMaster University EPC, publishing our evidence
tables, identifying the evidence and their rated strength,
providing the linkage between identiﬁed evidence and
each published recommendation, as well as publishing the
rationale for the resultant strength of recommendation,
this guideline effort represents the most rigorous, and
transparently veriﬁable, clinical practice parameter guide-
lines effort for metastatic brain tumors yet achieved.
Furthermore, this effort is more up-to-date at time of
publication than many previous guidelines efforts, in large
part due to the assistance of the McMaster University EPC
in facilitating a 13 month start-completion timeline. Given
that most guideline projects take over three years to com-
plete, and have an average evidence obsolescence shelf-life
of approximately ﬁve to seven years, our expedited time-
line will hopefully lead to maximal clinical impact for a
longer duration than previous efforts.
Lastly, we stronglybelieve that any set of comprehensive
brain metastasis guidelines should not merely serve as a
reﬂection of the best currently-available evidence, but
should also shine a light on critical unanswered questions to
develop new pathways for future treatments. We also
designed these guidelines to support the academic mission
of our colleagues in institutions around the country who are
seeking to discover the next frontiers in neuro-oncology. To
these ends, every chapter, whenever available, lists impor-
tant needed areas of study and future directions for various
clinical scenarios, and also outlines a current list of open
clinical trials comparing one brain metastasis treatment
modality to another—including treatments in radiotherapy,
stereotactic radiosurgery, surgery and chemotherapy as well
as treatments utilizing novel, emerging agents and combi-
nation therapies. Clinicians are encouraged to use these
listingstosupportandenrolltheirpatientsintheseimportant
ongoing studies so that when these guidelines are updated in
a few years, much more powerful evidence may exist for
adopting one treatment regimen over another.
Ranking clinical treatment scenarios by levels
of recommendation
As described in more detail in the following methodology
chapter, every clinical treatment scenario involving brain
metastases was highlighted and ranked by a level of rec-
ommendation, with Level 1 being the highest, and Level 3
the lowest, with sometimes no recommendations being
made depending on the quantity and quality of the evi-
dence. Rigorous and lively debate ensued between all of
the authors, but ultimately every author on the writing
panel agreed to all of the ultimate recommendations after a
careful review of the evidence itself and the strength of the
evidence. The panel’s strict adherence to the two-step
systematic review process, in collaboration with our
McMaster EPC partners, highlights a critically important
and unique feature of this effort. As might be expected,
given its rapidly emerging role in the treatment of brain
metastases over the past decade, the SRS recommendations
engendered the most spirited discussions amongst our
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tion was carefully constructed to stay fully within the
conﬁnes of the power of the evidence in a process fully
supported and endorsed by all members of the panel. With
a clear recognition of both their limitations and promise,
these clinical treatment scenarios and recommendations
have been organized into the following chapters:
I. Radiation therapy in newly-diagnosed brain metastases
II. Surgical resection in newly-diagnosed brain metas-
tases
III. Stereotactic radiosurgery in newly-diagnosed brain
metastases
IV. Chemotherapy in newly-diagnosed brain metastases
V. Re-treatment modalities for recurrent and/or progres-
sive brain metastases
VI. The role of prophylactic anticonvulsants in brain
metastases
VII. The role of steroid therapy in brain metastases
VIII. Novel and investigational therapies for brain metas-
tases
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